Delve into Sanofi's "play to win" strategy as investments are ramping up after their consumer health division's divestment.

However, Paul Hudson, CEO of Sanofi, one of the world's leading biopharmaceutical companies, says executives may need to rein ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

Another French private equity, PAI Partners, reportedly raised its bid for Sanofi’s consumer health division by around 200 million euros ($217.12 million). While CD&R has emerged as the ...

PARIS, Oct 20 (Reuters) - Sanofi (SASY.PA), opens new tab on Sunday reached an agreement on terms to sell a controlling stake in its consumer health unit Opella to U.S. private equity firm Clayton ...

Sanofi’s decision to cancel the spin-off ... Its healthcare solutions are available in more than 180 countries worldwide. Consumer Health Company (Opella) (Sold-Out entity) Headquartered in ...

PARIS (Reuters) -Sanofi on Sunday reached an agreement on terms to sell a controlling stake in its consumer health unit Opella to U.S. private equity firm Clayton Dubilier & Rice (CD&R), French ...

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% controlling stake in its consumer health business Opella. With the French ...

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including World <a target=_blank ...

Sanofi and CD&R enter exclusive talks to sell a 50% stake in Opella, Sanofi's consumer health unit, valued at $17.4 billion. Opella serves over 500M consumers globally with top brands like Allegra ...

Sanofi and CD&R are joining forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare ... rising income levels and greater health and well-being awareness, Sanofi ...

(Bloomberg) -- Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail ...